Lilly Just Ghosted a $960 Million Drug Deal

Lilly's Bigger Game

To understand why Lilly dropped RIPK1, you have to understand what Lilly is chasing.

The company posted $19.3 billion in revenue in Q4 2025 alone, fueled largely by its GLP-1 drugs for obesity and diabetes (think Mounjaro and Zepbound). That success has given Lilly both the resources and the confidence to be ruthlessly selective about what stays in the pipeline.

In February 2026, Lilly cut three other clinical programs in a single sweep: a gene therapy for a rare form of dementia, an anti-CD19 antibody for multiple sclerosis and rheumatoid arthritis, and a radioligand therapy for prostate cancer. None failed on safety; they just didn't clear what Lilly called their "differentiation bar."

It's pouring more than $50 billion into manufacturing. And its new programs span cardiovascular disease, Alzheimer's, oncology, and genetic medicines.

In other words, Lilly isn't cutting because it's struggling. It's cutting because it can afford to bet only on things it believes will be blockbusters. RIPK1 inhibitors, apparently, didn't make that list.

The Lonely Road Ahead for RIPK1

Rigel now gets all its RIPK1 assets back, which sounds like a consolation prize at best. The company loses its entire future milestone and royalty stream from the Lilly deal. No more checks in the mail.

To be fair, Rigel isn't in crisis mode. The company projected $275 to $290 million in total 2026 revenue, driven mostly by its blood disorder drug Tavalisse. Analysts still have a median price target of $50 on the stock (it trades around $32), and the consensus rating is a Strong Buy. But those projections were built before this termination was factored in, and losing a partner like Lilly changes the calculus on any asset.

The bigger question is whether anyone else wants RIPK1 inhibitors right now. The landscape isn't exactly thriving. Genentech already terminated its own Phase 2 RIPK1 program. Sanofi had a RIPK1 candidate in a Phase 2 trial for cutaneous lupus, but that program was discontinued in October 2023 after failing to meet its primary endpoint. The field has yet to produce a single approved drug.

Why RIPK1 Is So Hard to Crack

The science behind RIPK1 makes a compelling pitch on paper. The protein sits at a crossroads of inflammation and cell death, playing roles in diseases from rheumatoid arthritis to Alzheimer's to ALS. Blocking it in mice reduces brain inflammation, limits amyloid buildup, and protects vulnerable cell types.

But getting from "works in mice" to "works in humans" is where biotech dreams go to die. RIPK1 has a dual personality: it controls cell death and it serves as a structural scaffold for other signaling pathways. Inhibiting its kinase activity without disrupting those scaffold functions requires a surgical precision that's proven elusive. There's also the risk of broad immunosuppression, since RIPK1 is deeply woven into the body's TNF receptor signaling (the same pathway targeted by blockbuster drugs like Humira).

And for brain diseases, you need a drug that actually crosses the blood-brain barrier, a notoriously difficult engineering challenge that adds another layer of complexity.

The Bottom Line

Lilly's exit from RIPK1 isn't just a partnership dissolution; it's a signal. When a company with $19 billion quarters and a reputation for aggressive dealmaking decides a target isn't worth pursuing, the rest of the industry notices.

Rigel will evaluate its options. Maybe another partner emerges. Maybe the Phase 2a data (if it's ever completed) tells a different story. But for now, RIPK1 inhibitors are a therapeutic class with a lot of promise, a lot of failed experiments, and zero approved drugs.

Sometimes the most interesting molecule in the room still can't get a date.

Novartis Just Spent $925M on a Drug That Can't Beat the Reigning Champ

Novartis killed two late-stage trials for its next-gen blood thinner after it couldn't outperform Eliquis, the $14.4 billion anticoagulant behemoth. The $925 million bet on abelacimab just got a lot narrower, and the implications ripple across the entire Factor XIa race.